Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
MassRoots (MSRT) Looks to Become First Cannabis-Related Stock Listed on the Nasdaq with IPO Filing
-
Cemtrex (CETX) Announces Filing of S-3 Registration Statement
-
Caesarstone Sdot-Yam (CSTE) on Watch as Kibbutz Sdot Yam Could Sell Its Entire Stake
-
Amicus Therapeutics (FOLD) Could Be Worth More Than $22.50/Share in a Takeout - Chardan Capital
-
PlacementTracker Publishes Q1 2016 PIPE Market League Tables
-
Chardan Capital Markets Starts CaesarStone Sdot-Yam (CSTE) at Buy
-
Chardan Capital Markets Starts Dicerna Pharmaceuticals (DRNA) at Neutral
-
Chardan Capital Markets Starts Alnylam Pharmaceuticals (ALNY) at Buy
-
Chardan Capital Markets Starts Novavax (NVAX) at Neutral
-
Notable Analyst Rating Changes 3/28: (PRXL) (FINL) (THG) Upgraded; (XONE) (PH) (ATW) Downgraded
-
Chardan Capital Markets Starts AveXis (AVXS) at Buy
-
Green Shoots in uniQure (QURE) POC Data - Chardan Capital Markets
-
The Medicines Company (MDCO) PT Lifted to $65 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Regeneron Pharma (REGN) to Sell
-
StemCells, Inc. Announces Closing of $8 Million Public Offering
-
Energous (WATT) Catalysts To Profitability Begin In 2Q16 - Chardan Capital Markets
-
Chardan Capital Markets Downgrades BCommunication Ltd. (BCOM) to Neutral
-
StemCells (STEM) Prices $11M Stock, Warrants Offering
-
StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million
-
Jensyn Acquisition Corporation Completes $39.0 Million Initial Public Offering
-
Chardan Capital Markets Cuts Price target on Ambarella (AMBA) to $50 as Growth Continues to Slow
-
Jensyn Acquisition Corp. Announces Pricing of Initial Public Offering
-
Unique Fabricating, Inc. Reports Fourth Quarter and Full Year 2015 Results
-
Chardan Capital Markets Downgrades DigitalGlobe (DGI) to Neutral
-
Chardan Capital Markets Upgrades The KEYW Holding Corporation (KEYW) to Buy
-
Amarantus Announces $3M Capital Infusion
-
Chardan Capital Markets Downgrades Mesoblast Limited (MESO) to Neutral
-
Chardan Capital Markets Starts BioTime, Inc. (BTX) at Buy
-
UPDATE: Chardan Capital Markets Upgrades Regeneron Pharma (REGN) to Neutral
-
AveXis (AVXS) IPO Opens Down 10%
-
AveXis Announces Pricing of Initial Public Offering
-
Notable Analyst Rating Changes 2/10: (TDG) (DF) (SCTY) Upgraded; (XL) (KNX) (AINV) Downgraded
-
UPDATE: Chardan Capital Markets Starts iRobot Corporation (IRBT) at Buy
-
22nd Century Group (XXII) Enters $5.5M Common Stock, Warrants Registered Direct Offering
-
22nd Century Group Announces $5.5 Million Registered Direct Offering
-
Chardan Capital Markets Downgrades Profire Energy (PFIE) to Neutral
-
Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
-
Notable Analyst Rating Changes 1/25: (RSYS) (HD) (JBHT) Upgraded; (REGN) (TWTR) (WFM) Downgraded
-
Chardan Capital Markets Upgrades Voyager Therapeutics (VYGR) to Neutral
-
Chardan Capital Markets Downgrades Regeneron Pharma (REGN) to Sell
-
Inventergy Global (INVT) Announces $2.5M Conv. Preferred, Warrants Private Placement
-
Inventergy Announces Private Placement of $2.5 Million
-
AveXis (AVXS) Files $115M IPO
-
Chardan Closes Biotie/Axovant (AXON) Preference Following Acorda Deal; Reaffirms at 'Sell'
-
Chardan Capital Markets acts as Sole Placement Agent for PierianDx in its $9.25 Million Series A Financing
-
Chardan Capital Markets Starts Ituran Location & Control (ITRN) at Buy
-
Ambarella (AMBA): New Products Should Help it Break Free From the GoPro Curse - Chardan Capital Markets
-
Perion (PERI) Undervalued Relative to Mobile Ad Potential; Chardan Reaffirms at 'Buy'
-
PlacementTracker Publishes 2015 PIPE Market League Tables
-
Chardan Capital Markets Starts IDI, Inc. (IDI) at Buy, PT of $12.50

